Immunology and immunotherapy in the complex treatment of malignant tumors

• Main Authors: V. F. Semiglazov, A. I. Tseluiko, I. A. Baldueva, T. L. Nekhaeva, A. S. Artemyeva, A. G. Kudaybergenova, S. A. Protsenko, A. V. Novik, V. V. Semiglazov, R. V. Donskikh, T. Yu. Semiglazova, R. S. Pesotskiy, V. S. Apollonova, P. V. Krivorotko, A. M. Belyaev
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2021-04-01
• Series: Медицинский совет
• Subjects: immunotherapy; malignant tumors; t-lymphocytes; pd 1; pd-l1; prognosis
• Online Access: https://www.med-sovet.pro/jour/article/view/6116
• ISSN: 2079-701X; 2658-5790

Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials of different types of tumours. In recent years, a checkpoint inhibition therapy with monoclonal antibodies that target cytological T-lymphocytes has been developed. Thus, inhibition of two regulator genes CTLA 4 and PD1 or PD-L1 ligand to it is able to restore mediated T-cell tumour regression in its many localizations. The article considers a number of key fields of immunology and immunotherapy through a specific example of breast cancer (BC): the role of T-lymphocytes, vaccines, biomarkers of immunotherapy. The treatment used by the authors was based on an innovative technology of autologous dendritic cell-based vaccine based on highly immunogenic cancer/testis antigens (CTA) for immunotherapy of malignant tumours. The technology of specific CTA+-activated autologous dendritic cells (DC)-based immunotherapy was chosen as an innovative solution for the treatment of breast cancer patients. The treatment results showed that a clinically significant anti-tumour effect was achieved in 73.7% of patients. Median disease-free survival was 8.3 months (95% Cl 6.5-9.9 months), no grade 3-4 complications were recorded, grade 1-2 complications were observed in 57% of patients. The immunological effect in laboratory tests was recorded in 92% of patients. Thus, autologous DCs loaded with cancer/testis antigens can be considered as palliative dendritic vaccine therapy in patients with metastatic breast cancer who have exhausted standard treatment options. Also, the authors presented the results of immunological studies of the prognostic and predictive significance of the immunological response from the perspective of pathomorphology and general immunology, including tumour-infiltrating T-lymphocytes (TILs, CD3, CD4, CD8), their quantitative ratio and correlation with regulatory genes (PD-1, PD- L1, FOX-P3). The results of overall analysis comprising data of 2,148 patients from 9 centers confirmed the strong prognostic role of stromal tumour-infiltrating lymphocytes (sTILs) in early triple-negative breast cancer.